Table 3 Association between rs1801157 polymorphism and clinicopathological parameters

Age

  > 49/≤49

156/91

85/78

11/5

96/83

 OR (95% CI)

1.00 (references)

0.64(0.42–0.95)

1.28(0.45–4.18)

0.67(0.46–1.00)

 p

0.027*

0.653

0.049*

BMI (kg/m²)

 ≥ 23/ < 23

88/159

71/92

7/9

78/101

 OR (95% CI)

1.00 (references)

1.39(0.93–2.09)

1.41(0.49–3.90)

1.40(0.94–2.07)

 P

0.107

0.514

0.097

Menstrual status

 Yes/no

163/84

97/66

12/4

109/70

 OR (95% CI)

1.00 (references)

0.76(0.50–1.14)

1.55(0.52–5.66)

0.80(0.54–1.20)

 p

0.183

0.462

0.28

Tumor size (cm)

  > 2/≤ 2

126/121

90/73

8/8

98/81

 OR (95% CI)

1.00 (references)

1.18(0.80–1.76)

0.96(0.34–2.69)

1.16(0.79–1.71)

 p

0.404

0.937

0.446

Metastasis

 Positive/negative

122/125

96/67

4/12

100/79

 OR (95% CI)

1.00 (references)

1.47(0.99–2.19)

0.34(0.09–1.01)

1.30(0.88–1.91)

 p

0.06

0.069

0.187

TNM stage

 III-IV/I-II

62/185

60/103

4/12

64/115

 OR (95% CI)

1.00 (references)

1.74(1.13–2.67)

0.99(0.27–2.97)

1.66(1.09–2.53)

 p

0.012*

0.992

0.018

ER

 Positive/negative

155/92

120/43

13/3

153/46

 OR (95% CI)

1.00 (references)

1.66(1.08–2.57)

2.57(0.80–11.4)

1.72(1.13–2.63)

 p

0.023*

0. 149

0.012*

PR

 Positive/negative

136/111

97/66

9/7

106/73

 OR (95% CI)

1.00 (references)

1.20(0.80–1.79)

1.05(0.38–3.02)

1.19(0.80–1.75)

 p

0.374

0.926

0.393

Her-2

 Positive/negative

106/41

70/93

5/11

75/104

 OR (95% CI)

1.00 (references)

1.00(0.67–1.49)

0.60(0.19–1.72)

0.96(0.65–1.42)

 p

0.995

0.364

0.834